NCT07879768Not yet recruiting
Acupuncture and Laser Acupuncture for Advanced Non-Small Cell Lung Cancer
A Three-Arm Randomized Controlled Trial of Needle Acupuncture and Laser Acupuncture as Supportive Care for Patients With Advanced Non-Small Cell Lung Cancer
Source: ClinicalTrials.gov · Last updated 19 Oct 2026
Brief summary (registry, in English)
This three-arm randomized controlled clinical trial evaluates the clinical efficacy and safety of needle acupuncture and laser acupuncture compared with placebo (sham) laser acupuncture as supportive care for patients with advanced non-small cell lung cancer (NSCLC, Stage IIIB-IV). The study aims to investigate improvements in lung cancer-specific quality of life, symptom burden, functional status, and sleep quality over a 6 to 8-week intervention period.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- First submitted
- 29 Sept 2026
- Start date
- 1 Oct 2026
- Primary completion date
- 31 Jul 2029
- Lead sponsor
- China Medical University, Taiwan
- Diseases
- Lung cancer
- NCT number
- NCT07879768
What you commit to
- Study type: Interventional
- Planned participants: 90
- From 1 Oct 2026 to the primary completion date, 31 Jul 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent participation in another interventional supportive-care trial
- Received acupuncture treatment within the last three months
Other illness
- Bleeding tendency or severe thrombocytopenia contraindicating acupuncture
- Unstable cardiopulmonary disease or active systemic infection
- Local skin infection at proposed acupuncture sites
- Cognitive impairment preventing completion of questionnaires
Who the study is looking for
- Adults aged \>= 18 years
- Histologically or cytologically confirmed non-small cell lung cancer (NSCLC), Stage IIIB/IIIC or stage IV disease
- Receiving or planned to receive standard of care systemic therapy, radiotherapy, or best supportive care
- ECOG performance status 0-2
- Presence of at least moderate symptom burden (e.g., dyspnea, fatigue, pain, sleep disturbance, or impaired quality of life)
- Ability to provide written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| China Medical University Hospital Coordinator of this site? Confirm its status | Taichung | Taiwan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.